Showing results (61-70 of 193) with videos related to
Sort By:
Pageof 20
BMC Medicine|June 18, 2019
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysisJoshua D Wallach, Anita T Luxkaranayagam, Sanket S Dhruva, et al.Heart Rhythm|August 30, 2021
Electrical abnormalities with St. Jude/Abbott pacing leads: A systematic review and meta-analysisRoshni V Khatiwala, Elizabeth Mullins, Dali Fan, et al.JAMA Network Open|May 11, 2019
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or CommitmentsJoshua J Skydel, Anita T Luxkaranayagam, Sanket S Dhruva, et al.The American Journal of Managed Care|November 1, 2017
Association between FDA black box warnings and Medicare formulary coverage changesSanket S Dhruva, Pinar Karaca-Mandic, Nilay D Shah, et al.Expert Opinion on Drug Safety|December 8, 2017
New and incremental FDA black box warnings from 2008 to 2015Michael T Solotke, Sanket S Dhruva, Nicholas S Downing, et al.Inquiry : a Journal of Medical Care Organization, Provision and Financing|September 4, 2024
Nursing Home Certificate of Need Moratoria During the COVID-19 Pandemic Had Little Impact on AccessAnthony Yu, Christopher WhaleyAMA Journal of Ethics|November 7, 2022
If Patients Don't Use Available Health Service Pricing Information, Is Transparency Still Important?Christopher Whaley, Austin FraktHealth Affairs (Project Hope)|November 6, 2023
Studies Of Prescription Digital Therapeutics Often Lack Rigor And InclusivityAnika Kumar, Joseph S Ross, Nisarg A Patel, et al.Annals of Internal Medicine|September 16, 2024
Class I Recalls of Cardiovascular Devices Between 2013 and 2022 : A Cross-Sectional AnalysisClaudia See, Maryam Mooghali, Sanket S Dhruva, et al.LGBT Health|April 9, 2020
Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender IndividualsMichael T Solotke, Patrick Liu, Sanket S Dhruva, et al.Pageof 20